Treatment of Cancer-Associated Anaemia: Results from a Two-Day Cross-Sectional Survey in Germany

Schmitz, Stephan

doi:10.1159/000350306

Cited by 19 publications

(17 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Findings strikingly similar to this study’s were reported in a retrospective observational study in France ( N = 276) and a recent cross-sectional survey in Germany ( N = 3,867) [42, 43]. Both studies showed frequent use of RBC transfusions in anaemic cancer patients and disregard of available treatment options for iron deficiency.…”

Section: Discussionsupporting

confidence: 90%

A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia

Ludwig

Aapro

Bokemeyer

et al. 2014

Support Care Cancer

View full text Add to dashboard Cite

PurposePatients with cancer frequently experience chemotherapy-induced anaemia (CIA) and iron deficiency. Erythropoiesis-stimulating agents (ESAs), iron supplementation and blood transfusions are available therapies. This study evaluated routine practice in CIA management.MethodsMedical oncologists and/or haematologists from nine European countries (n = 375) were surveyed on their last five cancer patients treated for CIA (n = 1,730). Information was collected on tests performed at diagnosis of anaemia, levels of haemoglobin (Hb), serum ferritin and transferrin saturation (TSAT), as well as applied anaemia therapies.ResultsDiagnostic tests and therapies for CIA varied across Europe. Anaemia and iron status were mainly assessed by Hb (94 %) and ferritin (48 %) measurements. TSAT was only tested in 14 %. At anaemia diagnosis, 74 % of patients had Hb ≤10 g/dL, including 15 % with severe anaemia (Hb <8 g/dL). Low-iron levels (ferritin ≤100 ng/mL) were detected in 42 % of evaluated patients. ESA was used in 63 % of patients, blood transfusions in 52 % and iron supplementation in 31 % (74 % oral, 26 % intravenous iron). Only 30 % of ESA-treated patients received a combination of ESA and iron supplementation. Blood transfusions formed part of a regular anaemia treatment regimen in 76 % of transfused patients. Management practices were similar in 2009 and 2011.ConclusionManagement of anaemia and iron status in patients treated for CIA varies substantially across Europe. Iron status is only assessed in half of the patients. In contrast to clinical evidence, iron treatment is underutilised and mainly based on oral iron supplementation. Implementation of guidelines needs to be increased to minimize the use of blood transfusions.

show abstract

Section: Discussionsupporting

confidence: 90%

A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia

Ludwig

Aapro

Bokemeyer

et al. 2014

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…The present data are however very different from those collected in France in 2006 and published by Guardiola et al [24]. Their analysis reported that 17 % of anemic patients were not treated for anemia, while a German analysis from a Web-based prospective survey conducted in 2009-2010 [25] showed that two thirds of patients with Hb ≤12 g/dL were not treated for anemia.…”

Section: Discussioncontrasting

confidence: 98%

“…Nevertheless, the most recent large-scale studies still maintain that anemia and iron deficiency are underdiagnosed [21,22] and often inadequately treated [14,[23][24][25].…”

Section: Introductionmentioning

confidence: 99%

Management of anemia and iron deficiency in a cancer center in France

Lai-Tiong

Brami

Dubroeucq

et al. 2015

Support Care Cancer

View full text Add to dashboard Cite

An ideal medical setting for the management of anemia and iron deficiency, and the associated quality-of-life concerns, has yet to be defined for patients with cancer. Screening and treatment of mild to moderate anemia are inadequate, despite the advent of erythropoiesis-stimulating agents. Large scale, multicenter studies are required to define a clear medical framework for the management of anemia and iron deficiency.

show abstract

“…Anemia is a common problem in patients with cancer [3, 4, 35]. Although it has a negative impact on prognosis and treatment results, anemia is undertreated and is not a major concern among oncologists [4, 35].…”

Section: Discussionmentioning

confidence: 99%

Is there any role of intravenous iron for the treatment of anemia in cancer?

et al. 2016

View full text Add to dashboard Cite

BackgroundAnemia is a major cause of morbidity in patients with cancer resulting in poor physical performance, prognosis and therapy outcome. The aim of this study is to assess the efficacy of intravenous (iv) iron administration for the correction of anemia, for the prevention of exacerbation of anemia, for decreasing blood transfusion rates, and for the survival of cancer patients.MethodsPatients with different solid tumor diagnosis who received iv iron during their cancer treatment were evaluated retrospectively. Sixty-three patients with hemoglobin (Hgb) levels between ≥ 9 g/dL, and ≤ 10 g/dL, and no urgent need for red blood cell transfusion were included in this retrospective analysis. The aim of cancer treatment was palliative for metastatic patients (36 out of 63), or adjuvant or curative for patients with localized disease (27 out of 63). All the patients received 100 mg of iron sucrose which was delivered intravenously in 100 mL of saline solution, infused within 30 min, 5 infusions every other day. Complete blood count, serum iron, and ferritin levels before and at every 1 to 3 months subsequently after iv iron administration were followed regularly.ResultsInitial mean serum Hgb, serum ferritin and serum iron levels were 9.33 g/dL, 156 ng/mL, and 35.9 μg/dL respectively. Mean Hgb, ferritin, and iron levels 1 to 3 months, and 6 to 12 months after iv iron administration were 10.4 g/dL, 11.2 g/dL, 298.6 ng/mL, 296.7 ng/mL, and 71.6 μg/dL, 67.7 μg/dL respectively with a statistically significant increase in the levels (p < 0.001). Nineteen patients (30 %) however had further decrease in Hgb levels despite iv iron administration, and blood transfusion was necessary in 18 of these 19 patients (28.5 %). The 1-year overall survival rates differed in metastatic cancer patients depending on their response to iv iron; 61.1 % in responders versus 35.3 % in non-responders, (p = 0.005), furthermore response to iv iron correlated with tumor response to cancer treatment, and this relation was statistically significant, (p < 0.001).ConclusionsIv iron administration in cancer patients undergoing active oncologic treatment is an effective and safe measure for correction of anemia, and prevention of worsening of anemia. Amelioration of anemia and increase in Hgb levels with iv iron administration in patients with disseminated cancer is associated with increased tumor response to oncologic treatment and overall survival. Response to iv iron may be both a prognostic and a predictive factor for response to cancer treatment and survival.

show abstract

Treatment of Cancer-Associated Anaemia: Results from a Two-Day Cross-Sectional Survey in Germany

Cited by 19 publications

References 43 publications

A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia

A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia

Management of anemia and iron deficiency in a cancer center in France

Is there any role of intravenous iron for the treatment of anemia in cancer?

Contact Info

Product

Resources

About